Peginterferon Alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B

New England Journal of Medicine

Volumn 351, Issue 12, 2004, Pages 1206-1217

  Marcellin, Patrick ^a   Lau, George K K ^b   Bonino, Ferruccio ^c   Farci, Patrizia ^d   Hadziyannis, Stephanos ^e   Jin, Rui ^f   Lu, Zhi Meng ^g   Piratvisuth, Teerha ^h   Germanidis, Georgios ⁱ   Yurdaydin, Cihan ^j   Diago, Moises ^k   Gurel, Selim ^l   Lai, Ming Yang ^m   Button, Peter ⁿ   Pluck, Nigel ⁿ  

^a BEAUJON HOSPITAL   (France)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

^c FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^d UNIVERSITY OF CAGLIARI   (Italy)

^e HENRY DUNANT HOSPITAL   (Greece)

^f CAPITAL MEDICAL UNIVERSITY   (China)

^g SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

^h Songklanakarin Hospital   (Thailand)

ⁱ PAPAGEORGIOU GENERAL HOSPITAL   (Greece)

^j ANKARA UNIVERSITY   (Turkey)

^k HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

^l ULUDAG UNIVERSITY   (Turkey)

^m NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

ⁿ NONE

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIVIRUS AGENT; HEPATITIS B SURFACE ANTIGEN; INTERFERON; LAMIVUDINE; PEGINTERFERON ALPHA2A; VIRUS DNA; ALPHA2A INTERFERON; HEPATITIS B(E) ANTIGEN; MACROGOL DERIVATIVE; PEGINTERFERON ALFA-2A;

ABDOMINAL PAIN; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALOPECIA; ANOREXIA; ARTHRALGIA; ARTICLE; BACKACHE; CHRONIC HEPATITIS; CLINICAL TRIAL; COUGHING; DEPRESSION; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEMALE; FEVER; FOLLOW UP; HEADACHE; HEPATITIS B; HUMAN; INJECTION SITE; INSOMNIA; IRRITABILITY; LABORATORY TEST; LEUKOCYTE COUNT; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER FUNCTION TEST; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYALGIA; NAUSEA; NEUTROPENIA; PRIORITY JOURNAL; PRURITUS; RIGOR; SEROCONVERSION; SIDE EFFECT; SORE THROAT; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; VIRUS HEPATITIS; ADOLESCENT; BLOOD; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG COMBINATION; DRUG EFFECT; GENETICS; HEPATITIS B VIRUS; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; VIROLOGY;

ADOLESCENT; ADULT; AGED; ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; DNA, VIRAL; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; INTERFERON ALFA-2A; LAMIVUDINE; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS;

EID: 4544239807     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMoa040431     Document Type: Article

References (37)

1. Lai CL, Ratziu V, Yuen MF, Poynard T. Viral hepatitis B. Lancet 2003;362:2089-94.
2. Bonino F, Rosina F, Rizzetto M, et al. Chronic hepatitis in HBsAg carriers with serum HBV-DNA and anti-HBe. Gastroenterology 1986;90:1268-73.
3. Hadziyannis SJ, Vassilopoulos D. Hepatitis B e antigen-negative chronic hepatitis B. Hepatology 2001;34:617-24.
4. Funk ML, Rosenberg DM, Lok ASF. World-wide epidemiology of HBeAg-negative chronic hepatitis B and associated precore and core promoter variants. J Viral Hepat 2002;9:52-61.
5. Chu CJ, Keeffe EB, Han SH, et al. Prevalence of HBV precore/core promoter variants in the United States. Hepatology 2003;38:619-28.
6. EASL International Consensus Conference on Hepatitis B: 13-14 September, 2002 Geneva, Switzerland: consensus statement (long version). J Hepatol 2003;39:Suppl 1:S3-S25.
7. Manesis EK, Hadziyannis SJ. Interferon a treatment and retreatment of hepatitis B e antigen-negative chronic hepatitis B. Gastroenterology 2001;121:101-9.
8. Santantonio T, Mazzola M, Iacovazzi T, Miglietta A, Guastadisegni A, Pastore G. Long-term follow-up of patients with anti-HBe/HBV DNA-positive chronic hepatitis B treated for 12 months with lamivudine. J Hepatol 2000;32:300-6.
9. Tassopoulos NC, Volpes R, Pastore G, et al. Post lamivudine treatment follow up of patients with HBeAg negative chronic hepatitis B. J Hepatol 1999;30:Suppl 1:117. abstract.
10. Oliveri F, Santantonio T, Bellati G, et al. Long term response to therapy of chronic anti-HBe-positive hepatitis B is poor independent of type and schedule of interferon. Am J Gastroenterol 1999;94:1366-72.
11. Lok AS, McMahon BJ. Chronic hepatitis B: update of recommendations. Hepatology 2004;39:857-61.
12. Idem. AASLD Practice Guidelines 2003: chronic hepatitis B. (Accessed July 23, 2004, at http://www.aasld.org/netFORUMAASLD/eweb/docs/chronichep_B.pdf.)
13. Liaw YF, Leung N, Guan R, Lau GKK, Merican I. Asian-Pacific consensus statement on the management of chronic hepatitis B: an update. J Gastroenterol Hepatol 2003;18:239-45.
14. Liaw YF, Chien RN, Yeh CT, Tsai SL, Chu CM. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy. Hepatology 1999;30:567-72.
15. Hadziyannis SJ, Papatheodoridis GV, Dimou E, Laras A, Papaioannou C. Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B. Hepatology 2000;32:847-51.
16. Schalm SW, Heathcote J, Cianciara J, et al. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial. Gut 2000;46:562-8.
17. Barbaro G, Zechini F, Pellicelli AM, et al. Long-term efficacy of interferon alpha-2b and lamivudine in combination compared to lamivudine monotherapy in patients with chronic hepatitis B: an Italian multicenter, randomized trial. J Hepatol 2001;35:406-11.
18. Santantonio T, Niro GA, Sinisi E, et al. Lamivudine/interferon combination therapy in anti-HBe positive chronic hepatitis B patients: a controlled pilot study. J Hepatol 2002;36:799-804.
19. Bailon P, Palleroni A, Schaffer CA, et al. Rational design of a potent, long-lasting form of interferon: a 40 kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C. Bioconjug Chem 2001;12:195-202.
20. Perry CM, Jarvis B. Peginterferon-alpha-2a (40 kD): a review of its use in the management of chronic hepatitis C. Drugs 2001;61:2263-88.
21. Zeuzem S, Feinman SV, Rasenack J, et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000;343:1666-72.
22. Cooksley WGE, Piratvisuth T, Lee S-D, et al. Peginterferon α-2a (40KD): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B. J Viral Hepat 2003;10:298-305.
23. Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995;22:696-9.
24. Lok AS, Zoulim F, Locarnini S, et al. Monitoring drug resistance in chronic hepatitis B virus (HBV)-infected patients during lamivudine therapy, evaluation of performance of INNO-LiPA HBV DR assay. J Clin Microbiol 2002;40:3729-34.
25. Hadziyannis SJ, Alexopoulou A, Papakonstantinou A, Petraki K, Manesis E. Interferon treatment with or without oral ganciclovir in HBeAg-negative chronic hepatitis B: a randomized study. J Viral Hepat 2000;7:235-40.
26. Martinot-Peignoux M, Boyer N, Colombat M, et al. Serum hepatitis B virus DNA levels and liver histology in inactive HBsAg carriers. J Hepatol 2002;36:543-6.
27. Nair S, Perrillo RP. Serum alanine aminotransferase flares during interferon treatment in chronic hepatitis B: is sustained clearance of HBV DNA dependent on levels of pretreatment viremia? Hepatology 2001;34:1021-6.
28. Papatheodoridis GV, Manesis E, Hadziyannis SJ. The long-term outcome of interferon-alpha treated and untreated patients with HBeAg-negative chronic hepatitis B. J Hepatol 2001;34:306-13.
29. Brunetto MR, Oliveri F, Coco B, et al. Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients: a long term cohort study. J Hepatol 2002;36:263-70.
30. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 2003;348:800-7. [Erratum, N Engl J Med 2003;348:1192.]
31. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 2003;348:800-7. [Erratum, N Engl J Med 2003;348:1192.]
32. Janssen HLA, Senturk H, Zeuzem S. Peginterferon alfa-2b and lamivudine combination therapy compared with peginterferon alfa-2b for chronic HBeAg-positive hepatitis B: a randomized, controlled trial in 307 patients. Hepatology 2003;38:Suppl 1:246A. abstract.
33. Richman DD. The impact of drug resistance on the effectiveness of chemotherapy for chronic hepatitis B. Hepatology 2000;32:866-7.
34. Lampertico P, Del Ninno E, Vigano M, et al. Long-term suppression of hepatitis B e antigen-negative chronic hepatitis B by 24-month interferon therapy. Hepatology 2003;37:756-63.
35. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-82.
36. Koskinas J, Merkouraki P, Manesis E, Hadziyannis SJ. Assessment of depression in patients with chronic hepatitis: effect of interferon treatment. Dig Dis 2002;20:284-8.
37. Forton DM, Taylor-Robinson SD, Thomas HC. Cerebral dysfunction in chronic hepatitis C infection. J Viral Hepat 2003;10:81-6.